Quantbot Technologies LP Has $855,000 Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Quantbot Technologies LP increased its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 3.3% during the third quarter, HoldingsChannel.com reports. The fund owned 9,200 shares of the medical instruments supplier’s stock after purchasing an additional 292 shares during the period. Quantbot Technologies LP’s holdings in LeMaitre Vascular were worth $855,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in LMAT. NBC Securities Inc. boosted its position in LeMaitre Vascular by 73.2% during the third quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 183 shares during the period. GAMMA Investing LLC grew its stake in LeMaitre Vascular by 57.0% in the 2nd quarter. GAMMA Investing LLC now owns 548 shares of the medical instruments supplier’s stock valued at $45,000 after buying an additional 199 shares during the last quarter. West Oak Capital LLC bought a new position in LeMaitre Vascular in the 2nd quarter worth $58,000. USA Financial Formulas acquired a new position in LeMaitre Vascular during the 3rd quarter worth $60,000. Finally, nVerses Capital LLC boosted its holdings in LeMaitre Vascular by 33.3% during the second quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier’s stock valued at $66,000 after acquiring an additional 200 shares during the period. 84.64% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms have recently commented on LMAT. JMP Securities lifted their price objective on LeMaitre Vascular from $77.00 to $100.00 and gave the stock a “market outperform” rating in a research note on Tuesday, August 20th. Barrington Research lifted their price target on LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a research report on Friday, November 1st. StockNews.com cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. Cantor Fitzgerald initiated coverage on shares of LeMaitre Vascular in a research report on Tuesday, October 15th. They set a “neutral” rating and a $96.00 target price on the stock. Finally, Oppenheimer reiterated an “outperform” rating and set a $93.00 target price (up from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st. Three analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $94.57.

LeMaitre Vascular Price Performance

Shares of LeMaitre Vascular stock opened at $106.99 on Monday. The company’s fifty day moving average price is $95.52 and its two-hundred day moving average price is $88.03. The firm has a market capitalization of $2.41 billion, a PE ratio of 58.46, a price-to-earnings-growth ratio of 2.62 and a beta of 0.89. LeMaitre Vascular, Inc. has a 52-week low of $51.70 and a 52-week high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.05. The firm had revenue of $54.82 million during the quarter, compared to analyst estimates of $53.50 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The company’s quarterly revenue was up 15.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.33 earnings per share. Analysts predict that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 5th. Shareholders of record on Thursday, November 21st will be given a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a yield of 0.60%. The ex-dividend date is Thursday, November 21st. LeMaitre Vascular’s dividend payout ratio (DPR) is 34.97%.

Insiders Place Their Bets

In other LeMaitre Vascular news, Director Bridget A. Ross sold 3,750 shares of the company’s stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $101.47, for a total transaction of $380,512.50. Following the sale, the director now directly owns 2,278 shares of the company’s stock, valued at approximately $231,148.66. This represents a 62.21 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 10.79% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.